Skip to main content Skip to main navigation menu Skip to site footer
Review
Published: 30-09-2022

The role of intestinal and vaginal dysbiosis in endometrial cancer: an integrative review

Cancer Institute / Medical School of São Paulo University, Sao Paulo, Brazil
Endometrial cancer Dysbiosis Gut microbiome Vaginal microbiome

Abstract

The increase in the incidence of endometrial neoplasms in the female population is associated with increased life expectancy and the lifestyle adopted in our daily lives. The way we eat influences the profile of our bacterial flora and the production of substances that can work as suppressor tumors or oncogenic. Dysbiosis leads to changes in the intestinal and vaginal bacterial barrier and promotes chronic inflammation and metabolic and hormonal changes that influence the carcinogenesis of gynecological tumors. Chemotherapy treatments can also change the composition of the intestinal microbiota and influence the efficacy and toxic effects, as well as the quality of life of these patients. The use of prebiotics, probiotics, or fecal transplantation can be useful both in prevention and in obtaining better results with chemotherapy treatment and better quality of life. The objective of this review is to provide further elucidation about the interaction mechanisms between the intestinal microbiota and the gynecological tract and assess future perspectives through the modification of the feeding pattern, use of prebiotics, probiotics, and fecal transplant both in the prevention and during the treatment of carrier patients of endometrial neoplasm.

Metrics

Metrics Loading ...

References

  1. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. nature. 2006;444(7122):1027-31.
  2. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Frontiers in microbiology. 2016;7:979.
  3. Amabebe E, Anumba DO. Female gut and genital tract microbiota-induced crosstalk and differential effects of short-chain fatty acids on immune sequelae. Frontiers in Immunology. 2020;11.
  4. Amabebe E, Robert FO, Agbalalah T, Orubu ES. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. British Journal of Nutrition. 2020;123(10):1127-37.
  5. Huang G, Xu J, Lefever DE, Glenn TC, Nagy T, Guo TL. Genistein prevention of hyperglycemia and improvement of glucose tolerance in adult non-obese diabetic mice are associated with alterations of gut microbiome and immune homeostasis. Toxicology and applied pharmacology. 2017;332:138-48.
  6. Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. Journal of translational medicine. 2012;10(1):1-11.
  7. Plottel CS, Blaser MJ. Microbiome and malignancy. Cell host & microbe. 2011;10(4):324-35.
  8. Huang B, Zhao J, Li H, He K-L, Chen Y, Mayer L, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer research. 2005;65(12):5009-14.
  9. STILL. 2021.
  10. Belizário JE, Faintuch J. Microbiome and gut dysbiosis. Metabolic interaction in infection: Springer; 2018. p. 459-76.
  11. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. Journal of immunology research. 2015;2015.
  12. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA: a cancer journal for clinicians. 2019;69(4):258-79.
  13. Wilkinson, E. M., Ilhan, Z. E. & Herbst-Kralovetz, M. M. Microbiota-drug interactions: impact on metabolism and efficacy of therapeutics. Maturitas 112, 53–63 (2018).
  14. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M, Karpinets T, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
  15. Yan A, Culp E, Perry J, Lau JT, MacNeil LT, Surette MG, et al. Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS infectious diseases. 2018;4(1):68-76.
  16. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's and Colitis. 2014;8( 12):1569-81.
  17. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer–where do we stand? Molecular metabolism. 2020;33:102-21.
  18. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, et al. Influence of mediterranean diet on human gut microbiota. Nutrients. 2021;13(1):7.
  19. Van De Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PloS one. 2014;9(8):e105998.
  20. Walsh DM, Hokenstad AN, Chen J, Sung J, Jenkins GD, Chia N, et al. Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Scientific reports. 2019;9(1):1-16.

How to Cite

Sbragi, P. A. de O. F. (2022). The role of intestinal and vaginal dysbiosis in endometrial cancer: an integrative review. International Journal of Nutrology, 15(3). https://doi.org/10.54448/ijn22305